Abstract
Introduction Most guidelines recommend high-intensity statins for the secondary prevention of Acute Coronary Syndrome (ACS). However, it has been observed that South Asians are responsive to lower doses of statins to achieve the recommended target levels of low-density lipoprotein cholesterol (LDL-C). However, published data on this subject is limited. Therefore, we aim to compare the efficacy, safety and cost effectiveness of atorvastatin doses (80mg vs 40mg) in lowering the LDL-c levels to the less than 70 mg/dL within 12 weeks, among patients with incident ACS.
Methods and analysis This single-centre, prospective, randomised, controlled, open-labelled clinical trial is being conducted among patients naïve for statins presenting with incident ACS to the Colombo North Teaching Hospital, Ragama, Sri Lanka. All participants are randomised to two groups, to receive oral atorvastatin 40 mg nocte, or 80 mg nocte. The percentage of patients achieving treatment goals, the percentage with statin induced adverse drug reactions and the mean cost to achieve treatment goals will be compared between the two groups in 6,12 and 24 weeks. Outcome will be analysed for the intention-to-treat population.
Ethics and dissemination Ethical approval for this study has been obtained from the Ethics Review Committee of the Faculty of Medicine, University of Kelaniya (P/28/05/2022). This trial is registered in the Sri Lanka Clinical Trial Registry (SLCTR/2023/003). The results from this study will be disseminated as scientific publications in reputed journals.
Key points of this study What is already known on this topic?
While the European guideline recommendation is to initiate atorvastatin at 80 mg dose for ACS, it has been observed that South Asians respond well to lower dose. Additionally, South Asians tend to experience more adverse effects with higher doses of statins. However, reports on differential action of atorvastatin in South Asians is limited.
What this study adds?
This study explores the efficacy, safety, and cost-effectiveness of a lower dose of atorvastatin (40 mg daily) compared to guideline recommended dose of 80mg in a South Asian cohort.
How might this study affect research, practice or policy?
The findings may influence statin dose recommendation for South Asians/Sri Lankans which will help to reduce unnecessary side effects and be cost saving as well in secondary prevention of ACS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
SLCTR/2023/003
Funding Statement
This study was funded by Ceylon Collage of Physicians (CCP-Research Grant 2023).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Faculty of Medicine, University of Kelaniya gave ethical approval for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This work was supported by the Ceylon College of Physicians Research Grant (CCP-Research Grant 2023) awarded to SDS. Quality control materials for the biochemistry and the lipid panel were funded by the Analytical Instruments Pvt Ltd. Funding agency does not have any role in the study design, data collection, data analysis or publication of results.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos